Doxycycline does not prevent STIs among cisgender women
February 20, 2023 – Researchers from the University of Washington (UW), Kenya Medical Research Institute (KEMRI), and Hennepin Healthcare Research Institute (HHRI) announced results at CROI from a clinical trial demonstrating that doxycycline taken after sex does not prevent bacterial sexually transmitted infections (STIs) – chlamydia or gonorrhea – among cisgender women. The dPEP Kenya Trial was conducted in Kisumu, Kenya, to evaluate the effectiveness of doxycycline postexposure prophylaxis (PEP) to prevent bacterial STIs. The results of the study have been highly anticipated, as this is the first study of doxycycline PEP among cisgender ...









